PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study
Por um escritor misterioso
Descrição
Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records - ScienceDirect
Ranibizumab for the treatment of wet AMD: a summary of real-world studies
Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study, Health and Quality of Life Outcomes
End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration - ScienceDirect
Frontiers Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model
Ranibizumab reimbursement and treatment patterns for neovascular age-related macular degeneration in Taiwan – Results from the 12-month, observational RENOWNED study - ScienceDirect
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Cells, Free Full-Text
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
Extended intervals for wet AMD patients with high retreatment needs: informing the risk during COVID-19, data from real-world evidence
de
por adulto (o preço varia de acordo com o tamanho do grupo)
